WRCB, IIT Bombay: Commercializing Deep-Tech Innovation Custom Case Solution & Analysis

Evidence Brief: WRCB IIT Bombay

1. Financial Metrics

• Initial endowment: 5 million dollars provided by the Wadhwani Foundation in 2014.
• Project Portfolio: Over 30 research projects funded across various bioengineering domains.
• Funding Structure: Grants primarily support translational research moving from Technology Readiness Level 3 to Technology Readiness Level 7.
• Revenue Streams: Potential income from licensing fees, royalty payments, and equity stakes in spin-off companies, though significant realizations remain pending.

2. Operational Facts

• Location: Housed within the Indian Institute of Technology Bombay, utilizing existing institutional infrastructure and faculty expertise.
• Focus Areas: Healthcare diagnostics, drug delivery systems, point of care devices, and environmental bioengineering.
• Governance: Oversight provided by a steering committee comprising IIT Bombay leadership and donor representatives.
• Process: Annual call for proposals followed by a multi-stage review involving internal and external technical experts.

3. Stakeholder Positions

• Prof. Pramod Wangikar: Director of WRCB, focused on bridging the gap between academic publication and commercial availability.
• Romesh Wadhwani: Donor and Chairman of Wadhwani Foundation, seeking measurable societal impact and scalable business models from research.
• Faculty Researchers: Primary interest in academic rigor and publications, often lacking the business expertise or time required for commercialization.
• Industry Partners: Interested in de-risked technologies but often find academic timelines and intellectual property negotiations cumbersome.

4. Information Gaps

• Specific equity percentages held by WRCB in current startup spin-offs.
• Detailed breakdown of the burn rate for the initial 5 million dollar endowment.
• Historical success rate of projects reaching Technology Readiness Level 9 or full market entry.
• Specific regulatory approval timelines for the medical device pipeline.

Strategic Analysis

1. Core Strategic Question

• How should WRCB evolve its operating model to ensure that deep-tech innovations transition from successful lab prototypes to commercially viable products in a capital-intensive and highly regulated market?

2. Structural Analysis (Value Chain and Jobs-to-be-Done)

• The Research Value Chain: WRCB excels at the ideation and proof-of-concept stages. However, the chain breaks at the clinical validation and manufacturing scale-up phases due to a lack of specialized facilities and regulatory expertise.
• Jobs-to-be-Done: For faculty, WRCB must handle the business development job so they can remain focused on science. For the market, WRCB must fulfill the job of de-risking unproven technologies before venture capital or industry players commit funds.
• Structural Barrier: The current model relies on faculty members to become entrepreneurs, which conflicts with their primary academic incentives and skill sets.

3. Strategic Options

• Option A: The Venture Studio Model. WRCB takes an active role in company formation by recruiting external CEOs to lead spin-offs while faculty remain technical advisors. This requires higher operational spending but increases the probability of market success.
• Option B: The Pure Licensing Engine. Shift focus entirely toward intellectual property packaging and licensing to established pharmaceutical and biotech firms. This minimizes execution risk but reduces the potential for high-growth equity returns.
• Option C: Industry-Sponsored Research Consortia. Form clusters of industry players who co-fund specific research tracks. This ensures market relevance from day one but may limit the radical innovation characteristic of deep-tech.

4. Preliminary Recommendation

Adopt the Venture Studio Model. Deep-tech commercialization in India lacks a mature pool of scientist-entrepreneurs. By separating the technical leadership from the business leadership, WRCB can accelerate the transition from the lab to the market while retaining higher equity stakes in high-potential ventures.

Implementation Roadmap

1. Critical Path

• Month 1-2: Establish an Entrepreneur in Residence program to attract business-oriented leaders for the top 3 most promising technologies.
• Month 3-4: Standardize the Intellectual Property transfer process between IIT Bombay and WRCB spin-offs to eliminate negotiation delays.
• Month 5-9: Launch a dedicated regulatory and clinical trial support desk to navigate the Central Drugs Standard Control Organization requirements.
• Month 10-12: Secure follow-on seed funding from external venture capital firms for the first cohort of studio-led startups.

2. Key Constraints

• Talent Scarcity: Finding experienced business leaders willing to take the risk of leading early-stage deep-tech startups.
• Regulatory Friction: The protracted timeline for medical device and drug approvals in the Indian market can exhaust initial grant funding.
• Conflict of Interest: Navigating the divide between faculty time commitments to the institute versus their involvement in commercial ventures.

3. Risk-Adjusted Implementation Strategy

Execution will focus on a phased pilot. Instead of applying the studio model to all 30 projects, WRCB will select 3 projects that have reached Technology Readiness Level 6. Success will be measured by the ability of these projects to secure external non-grant capital within 12 months. If the pilot fails to attract external investors, the center will pivot back to the licensing model to preserve the remaining endowment.

Executive Review and BLUF

1. BLUF

WRCB must transition from a passive grant-funding body to an active venture builder. The current bottleneck is not the quality of research but the absence of commercial leadership for individual projects. By implementing a venture studio model and recruiting external business heads, WRCB can bridge the gap between the lab and the market. This shift requires immediate prioritization of three high-potential technologies to demonstrate proof of concept for the new model. Failure to change the operating structure will result in a portfolio of sophisticated prototypes that never achieve societal or financial impact.

2. Dangerous Assumption

The analysis assumes that external business talent will be willing to lead deep-tech startups at Technology Readiness Level 4 or 5 without significant upfront compensation or guaranteed success. In the Indian market, high-quality business talent often prefers established sectors over the long gestation periods of bioengineering.

3. Unaddressed Risks

• Institutional Inertia: IIT Bombay may resist the aggressive commercialization and equity structures required for a venture studio model, citing academic neutrality. Probability: High. Consequence: Stalled implementation.
• Capital Intensity: The cost of clinical trials for bioengineering products can exceed the remaining WRCB funds. Probability: Moderate. Consequence: Projects fail during the final stages of validation.

4. Unconsidered Alternative

WRCB could pursue a Global Integration Strategy. Instead of focusing on the Indian market first, WRCB could partner with established international incubators in Boston or Singapore to license the technology where the regulatory and investment environment for deep-tech is more mature. This would accelerate revenue through foreign currency licensing fees while bypassing domestic infrastructure gaps.

5. Final Verdict

APPROVED FOR LEADERSHIP REVIEW